论坛 › 友链交换 › 2023年值得期待的10款癌症疫苗，病灶消失或延长存活期，瞄准多样癌种！

tw4ld6 发表于 2024-5-21 04:05:06

2023年值得期待的10款癌症疫苗，病灶消失或延长存活期，瞄准多样癌种！

<img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">关注<span style="color: black;">没</span>癌家园</strong><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;"><span style="color: black;">咱们</span>战癌到底</strong><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLsdd1gVKhaozdIbFrXHyjJrI3jSjGf2wDFOXbez9kvWCEtVmeH5UOiatnxCuktia1FbYvxdk6B3smg/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNg6KqSDRGkFCLqIzx6oQdnlvRFe5Kz6dTZgyJ6UmBQKNhTdJ5lSkK5tGD8eK5NzjRd1QkhHt5m9hA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;">随着<span style="color: black;">全世界</span>对癌症<span style="color: black;">科研</span>的<span style="color: black;">持续</span>深入，越来越多的细胞免疫疗法<span style="color: black;">面世</span>，足以<span style="color: black;">掌控</span>晚期癌症的<span style="color: black;">发展</span>，<span style="color: black;">加强</span>生活质量，延长寿命，<span style="color: black;">乃至</span>让<span style="color: black;">非常多</span>生命即将终结的晚期癌症<span style="color: black;">病人</span>奇迹重生！</span><span style="color: black;">癌症疫苗是一种主动免疫疗法，是肿瘤免疫疗法<span style="color: black;">行业</span>的<span style="color: black;">要紧</span><span style="color: black;">构成</span>部分，<span style="color: black;">经过</span>刺激或恢复人体<span style="color: black;">自己</span>的免疫系统，来防止癌症发展或杀灭现有的肿瘤 。<strong style="color: blue;">癌症疫苗<span style="color: black;">重点</span><span style="color: black;">包含</span><span style="color: black;">细胞疫苗、DNA 疫苗、mRNA 疫苗、多肽疫苗、树突状细胞疫苗、纳米疫苗</span>等，</strong><span style="color: black;">已然</span>在<strong style="color: blue;"><span style="color: black;">恶性黑色素瘤、肺癌、卵巢癌、宫颈癌等实体瘤</span></strong>治疗<span style="color: black;">行业</span>取得了<span style="color: black;">必定</span>的临床疗效，展现了良好的应用前景。</span><span style="color: black;">正值2023年年末之际，众多癌症疫苗的发展势头迅猛，备受广大癌友们期待和关注。今天<span style="color: black;">没</span>癌家园<span style="color: black;">博主</span>就给大家盘点下2023年值得期待的10款癌症疫苗，以供<span style="color: black;">大众</span>参考。</span><strong style="color: blue;"><span style="color: black;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">古巴肺癌疫苗</p>

      </span></strong><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKURicdriaPRGT0twwic9qEfoz44IOX76lhQOCvEc325IvBXrWfbWCoSGZWrP9kouY8Sjia0BjiaV707icQ/640?wx_fmt=gif&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;">古巴肺癌疫苗（<span style="color: black;">CIMAvax-EGF</span>）</strong></span><span style="color: black;">，<span style="color: black;">做为</span>世界上<span style="color: black;">第1</span>种针对非小细胞肺癌的治疗性疫苗，CIMAvax-EGF在2011年完<span style="color: black;">成为了</span>临床<span style="color: black;">实验</span>正式在古巴上市，其效果足够令人振奋，不同于预防性疫苗，这是一款治疗性疫苗，接受疫苗治疗的<span style="color: black;">病人</span><span style="color: black;">存活</span>期是未接受疫苗治疗<span style="color: black;">病人</span>的2倍。</span><strong style="color: blue;">1</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">5年<span style="color: black;">存活</span>率从0%飙升至23%！古巴肺癌疫苗疗效惊艳！</strong></p><span style="color: black;">2016年8月1日<span style="color: black;">发布</span>在《Clinical Cancer Research》国际知名杂志上的一项<span style="color: black;">评定</span>CIMAvax-EGF治疗晚期非小细胞肺癌<span style="color: black;">病人</span>的随机III期<span style="color: black;">实验</span>中<span style="color: black;">表示</span>，</span><span style="color: black;"><strong style="color: blue;">CIMAvax-EGF <span style="color: black;">加强</span>了一线化疗后<span style="color: black;">疾患</span><span style="color: black;">最少</span>稳定的晚期 NSCLC <span style="color: black;">病人</span>的中位总<span style="color: black;">存活</span>期。</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfJNTa6uwwkgVYbhlvygZqjGibWgB9QolL1hTfhSRqwTDg8nMGvdkicrNMgvrkLFL6FErUO9wXR7FwSw/640?wx_fmt=png&amp;from=appmsg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">截图源自</span><span style="color: black;">《</span><span style="color: black;">Clinical Cancer Research</span><span style="color: black;">》官网</span></span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">与接受最佳支持性护理<span style="color: black;">做为</span>维持治疗的对照<span style="color: black;">病人</span>相比，<span style="color: black;"><strong style="color: blue;"><span style="color: black;">身患</span>鳞状细胞癌或腺癌且血清 EGF 浓度高于870 pg/ml的<span style="color: black;">病人</span><span style="color: black;">拥有</span>更好的<span style="color: black;">存活</span>率，</strong></span>证实了肿瘤对 EGF 耗竭的<span style="color: black;">敏锐</span>性。&nbsp;</span></p><span style="color: black;">该<span style="color: black;">科研</span>纳入了2008年至2012年<span style="color: black;">时期</span> 405 名经组织学或细胞学证实为 IIIB 和 IV 期 NSCLC 的<span style="color: black;">病人</span>，其中氛围疫苗组270例，对照组135例。</span><strong style="color: blue;"><span style="color: black;">1. 完成诱导的疫苗接种<span style="color: black;">病人</span>的<span style="color: black;">中位总<span style="color: black;">存活</span>期为 12.43 个月</span>，而对照组为 9.43 个月 。</span></strong><strong style="color: blue;"><span style="color: black;">2. 血清EGF浓度高的<span style="color: black;">病人</span><span style="color: black;">存活</span><span style="color: black;">优良</span>更大。<span style="color: black;">在 EGF 水平 &gt;870 pg/ml 的<span style="color: black;">病人</span>中，绝对<span style="color: black;">存活</span>期延长了 5 个月。</span></span></strong><strong style="color: blue;"><span style="color: black;">3.接种疫苗的<span style="color: black;">病人</span>与对照<span style="color: black;">病人</span>的<span style="color: black;">长时间</span><span style="color: black;">存活</span>率较高<span style="color: black;">：37% vs 20%（2 年<span style="color: black;">存活</span>率）和 23% vs 0%（5 年<span style="color: black;">存活</span>率）。</span></span></strong><span style="color: black;"><span style="color: black;">按照</span>最新<span style="color: black;">颁布</span>的数据，<span style="color: black;"><strong style="color: blue;">肺鳞癌<span style="color: black;">病人</span>五年<span style="color: black;">存活</span>率分别为23% vs 0%，肺腺癌为18.2% vs 0%！对照组<span style="color: black;">无</span><span style="color: black;">病人</span>活过5年。</strong></span>此外，<span style="color: black;">拥有</span>更好免疫状态的<span style="color: black;">病人</span>受益<span style="color: black;">更加多</span>。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">其中<span style="color: black;">文案</span>还更新了两例<span style="color: black;">表率</span>性<span style="color: black;">病人</span>的CT扫描图，<span style="color: black;">她们</span>在<span style="color: black;"><strong style="color: blue;">接受CIMAvax-EGF疫苗治疗后，病情保持<span style="color: black;">长时间</span>稳定，<span style="color: black;">存活</span>期分别高达7年和8年，</strong></span>充分<span style="color: black;">表现</span>了CIMAvax-EGF疫苗延长<span style="color: black;">病人</span><span style="color: black;">存活</span>期，预防癌症复发的目的。</span></p><strong style="color: blue;"><span style="color: black;">好<span style="color: black;">信息</span>是，</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">国内<span style="color: black;">病人</span>现可<span style="color: black;">经过</span></span></strong></span><strong style="color: blue;"><span style="color: black;"><span style="color: black;"><span style="color: black;">没</span>癌家园医学部（400-626-9916）</span>，向古巴医疗<span style="color: black;">分部</span>申请肺癌疫苗，并<span style="color: black;">协同</span>标准治疗，以延长<span style="color: black;">存活</span>期，<span style="color: black;">加强</span>生活质量！</span></strong><strong style="color: blue;">2</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">近半数的<span style="color: black;">病人</span><span style="color: black;">存活</span>期≥2年，古巴肺癌疫苗开启长<span style="color: black;">存活</span>之路</strong></p><span style="color: black;">在2023年4月《J Cancer》上<span style="color: black;">发布</span>了Cimavax-EGF肺癌疫苗<span style="color: black;">做为</span>晚期非小细胞肺癌<span style="color: black;">病人</span>维持治疗的真实世界<span style="color: black;">科研</span>数据，其结果足以令人惊艳！</span><span style="color: black;">该<span style="color: black;">科研</span><span style="color: black;">选择</span>2015 年 1 月至 2017 年 12 月收治的106例18岁以上的IIIB 期和 IV 期非小细胞肺癌<span style="color: black;">病人</span>，在对一线治疗(<span style="color: black;">包含</span>铂双药、化学疗法和放射疗法或单药化学疗法)<span style="color: black;">表示</span>出客观反应或<span style="color: black;">疾患</span>稳定后，<span style="color: black;">起始</span>接受肺癌疫苗CIMAvax-EGF的治疗。一线治疗结束时<span style="color: black;">显现</span>脑转移或<span style="color: black;">疾患</span><span style="color: black;">发展</span>的<span style="color: black;">病人</span>被排除在外。</span><span style="color: black;">结果<span style="color: black;">表示</span>，化疗或化放疗<span style="color: black;">起始</span>后的中位总<span style="color: black;">存活</span>期为 22.46 个月（近乎2年），6、12 和 24 个月的<span style="color: black;">存活</span>率分别为 97.7%、82.7% 和 45.5% 。这<span style="color: black;">寓意</span>着近乎有一半的<span style="color: black;">病人</span><span style="color: black;">存活</span>期长达2年<span style="color: black;">乃至</span>更长。</span><span style="color: black;"><span style="color: black;">按照</span>年龄分析总<span style="color: black;">存活</span>期时，65岁以下<span style="color: black;">病人</span>的中位总<span style="color: black;">存活</span>期为 16.7 个月，而 65 岁以上<span style="color: black;">病人</span>的中位总生存期为 12.2 个月，这说明65岁以下的非小细胞肺癌<span style="color: black;">病人</span>受益更大。</span><span style="color: black;">关于体能状态，<span style="color: black;"><strong style="color: blue;">ECOG 0 <span style="color: black;">病人</span>的中位总<span style="color: black;">存活</span>期为29个月</strong></span>，而诊断时 ECOG-1 的<span style="color: black;">病人</span>的中位总<span style="color: black;">存活</span>期为11个月，<span style="color: black;"><strong style="color: blue;">这<span style="color: black;">显示</span>体能状态更好的<span style="color: black;">病人</span><span style="color: black;">存活</span>期会更长，将近翻了一倍！</strong></span></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">【<span style="color: black;">那些</span><span style="color: black;">病人</span>适合古巴肺癌疫苗？】</strong></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">经治疗后病情稳定的非小细胞肺癌</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">无</span>脑转移的非小细胞肺癌</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">初期</span>非小细胞肺癌</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">晚期非小细胞肺癌</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">手术后的非小细胞肺癌</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">肺鳞癌、肺腺癌<span style="color: black;">病人</span></span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNhygrMUvvMXhWqpQn05Nh7GT1IEGeCeudJYibpWGMre6cjdTa8uQdNnZCCpJ8N9USC5p3Vgw3ksRrQ/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">获突破性疗法认定！mRNA疫苗让黑色素癌复发或死亡<span style="color: black;">危害</span>下降44%</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLUTgZ95j30T5EYGIg8BiavQfYL8Lljc0z3ex5fH03JJ5ic4zZB3IVoARpDEToR9x52W77AKWHDakJw/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">在2023年ASCO会议上，Moderna和MSD<span style="color: black;">颁布</span>了一项最新结果，证明当mRNA疫苗与Keytruda (<span style="color: black;">帕博利珠单抗，</span>pembrolizumab) 联合<span style="color: black;">运用</span>时，可改善远处<span style="color: black;">没</span>转移<span style="color: black;">存活</span>期 (DMFS)。</span><span style="color: black;">在KEYNOTE-942<span style="color: black;">科研</span>中，联合<span style="color: black;">开发</span>的基于<span style="color: black;">病人</span>肿瘤DNA的个体化治疗mRNA-4157/V940疫苗，<span style="color: black;"><strong style="color: blue;">将高危III/IV期黑色素瘤<span style="color: black;">病人</span>的远处转移或死亡<span style="color: black;">危害</span>降低65%</strong></span>(HR=0.347) ，与Keytruda联合<span style="color: black;">运用</span>时与单独<span style="color: black;">运用</span> Keytruda 相比，报告的不良事件和安全性与之前的<span style="color: black;">发掘</span>一致。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">早在2023年2月23日，默沙东宣布，</span><strong style="color: blue;"><span style="color: black;">在研mRNA癌症疫苗mRNA-4157/V940联合Keytruda组合疗法获美国食品<span style="color: black;">药物</span>监督管理局（FDA）授予</span></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;">突破性疗法认定</span></strong></span><span style="color: black;">，</span><strong style="color: blue;"><span style="color: black;">用于高危黑色素瘤<span style="color: black;">病人</span>接受完全切除术后的辅助治疗。</span></strong></p><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">针对HPV阴性头颈癌<span style="color: black;">病人</span>，个体化新抗原疫苗TG4050表现优异</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKomxe9n5ZK7QVbRtc9yQbyEnYQRP0N5wSXjhZI9W45eeFkH32nb9HcTiaQKBje3S2Wt1ofzOTN9zA/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">在2023年ASCO大会上，Transgene和NEC<span style="color: black;">机构</span><span style="color: black;">颁布</span>了关于个体化新抗原癌症疫苗TG4050治疗HPV阴性头颈癌<span style="color: black;">病人</span>的1期临床<span style="color: black;">实验</span>的新数据。分析<span style="color: black;">表示</span>，<span style="color: black;">实验</span>中所有接受TG4050治疗的<span style="color: black;">病人</span>都产生了特异性免疫反应，正如额外免疫学测试的结果所证明的那样，并迄今为止保持<span style="color: black;">没</span>病状态。</span><strong style="color: blue;"><span style="color: black;">TG4050 是一种针对实体瘤<span style="color: black;">研发</span>的个体化免疫疗法，基于病毒载体个体化免疫治疗平台技术，并由NEC<span style="color: black;">长时间</span><span style="color: black;">累积</span>的人工智能（AI）专业知识<span style="color: black;">供给</span>支持。</span></strong><span style="color: black;">值得一提的是，此次<span style="color: black;">颁布</span>的数据<span style="color: black;">表示</span>，<span style="color: black;"><strong style="color: blue;">即使是<span style="color: black;">已然</span>被确认为PD-L1阴性或低表达的<span style="color: black;">病人</span>，<span style="color: black;">亦</span><span style="color: black;">一样</span>有理想的表现。</strong></span></span><span style="color: black;"><span style="color: black;">截止</span>2023年5月，头颈癌1期<span style="color: black;">实验</span>中已有32例<span style="color: black;">病人</span>进行了随机分组。<span style="color: black;"><strong style="color: blue;">所有接受TG4050治疗的16例<span style="color: black;">病人</span>保持缓解状态，中位随访时间为10.4个月。</strong></span>而对照组中有2例<span style="color: black;">拥有</span><span style="color: black;">类似</span>特性的<span style="color: black;">病人</span>产生复发，<span style="color: black;">另一</span>2例<span style="color: black;">病人</span><span style="color: black;">亦</span>表现出生化复发的迹象。<span style="color: black;">迄今</span>为止，该疫苗展现良好耐受性，<span style="color: black;">无</span><span style="color: black;">关联</span>严重不良事件的<span style="color: black;">出现</span>。Transgene和NEC计划该<span style="color: black;">实验</span>将在2024年中期实现18个月的中位随访，并进一步准备在2023年下半年<span style="color: black;">起步</span>头颈癌II期辅助<span style="color: black;">实验</span>。</span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKomxe9n5ZK7QVbRtc9yQbyQBChtOy8G8jtAYib09s3spxz7G0t0KFmsSR3EHb85E42r5nuZghKvqA/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">怎样</span>寻求个性化癌症疫苗治疗</strong></span><strong style="color: blue;">&gt;&gt;</strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">日前</span>，癌症疫苗中疗效及预防复发效果较为<span style="color: black;">明显</span>的当属</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">树突状细胞疫苗</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">及</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">个性化新抗原疫苗</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">等，在德国、日本<span style="color: black;">亦</span>有树突状细胞疫苗用于临床辅助治疗多种癌症，如肺癌、肝癌、肾癌、乳腺癌、皮肤癌等，这是癌症<span style="color: black;">病人</span>治疗的新<span style="color: black;">期盼</span>。</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">想寻求国内外治疗新技术<span style="color: black;">帮忙</span>的<span style="color: black;">病人</span>，</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">在经济<span style="color: black;">前提</span><span style="color: black;">准许</span>的<span style="color: black;">状况</span>下，<span style="color: black;">能够</span>先将病理报告、治疗经历及出院小结等资料提交至</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">没</span>癌家园医学部（400-626-9916）</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">进行初步<span style="color: black;">评定</span>。</span></strong></span><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNgYXibLKnSa1ZuoVqHicntSnO5NId4tkmQzz6icW3taPDvYvd0tYxp45G2VICZFrpvxFjk0fTaMxLHzQ/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></a><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">竟能破解PD-1耐药！新型肺癌疫苗TedopiⅢ期<span style="color: black;">实验</span>数据<span style="color: black;">颁布</span>！</p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfKDEJrNrdMbngSPtghZx9iabsY5Khw3OiaIHLcEAzoicorEHaxZD9hRF3wG3icvpibSRLQ3D3hpld8TDDg/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">2023年9月11日，《Annals of Oncology（肿瘤学年鉴）》刊登了同行评审的 T 细胞表位癌症疫苗Tedopi® （OSE-2101）在第三<span style="color: black;">周期</span>临床<span style="color: black;">实验</span>（ATALANTE-1）中取得的积极结果，<span style="color: black;">重点</span>用于在HLA-A2 阳性晚期或转移性非小细胞肺癌（NSCLC）<span style="color: black;">病人</span>单药治疗对免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂 (ICI) 继发耐药的三线 NSCLC <span style="color: black;">病人</span>。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfKDEJrNrdMbngSPtghZx9iabDWtATxZhByib17HK0T7HuGic8ZqGbjmtmJzB8ibB5ohMcAvUkAZ0TAbnw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">▲截自《Annals of Oncology》</span></strong></p><span style="color: black;">Tedopi® 是一种新型基于T细胞表位的癌症疫苗，针对五种肿瘤<span style="color: black;">关联</span>抗原，是一种激活和分化的现成免疫疗法，可扩大 HLA-A2 癌症<span style="color: black;">病人</span>的肿瘤特异性 T 淋巴细胞，<span style="color: black;">针对</span>在化疗和PD-1治疗后仍然存在<span style="color: black;">疾患</span><span style="color: black;">发展</span>的<span style="color: black;">病人</span>不失为一种安全且有效的治疗<span style="color: black;">办法</span>。</span><span style="color: black;">来自随机国际 3 期<span style="color: black;">科研</span>的积极数据<span style="color: black;">表示</span>，<strong style="color: blue;"><span style="color: black;">新型癌症疫苗 Tedopi®&nbsp;</span></strong>与标准护理多西他赛或培美曲塞化疗相比，<span style="color: black;"><strong style="color: blue;">单药治疗<span style="color: black;">拥有</span>更好的安全性和生活质量，可<span style="color: black;">加强</span>总体<span style="color: black;">存活</span>率，1年总<span style="color: black;">存活</span>率为44.4%，<span style="color: black;">显著</span>优于化疗的27.5%。</strong></span></span><span style="color: black;">截止到2021年1月15日，中位随访 24.8 个月后，Tedopi®组的中位总<span style="color: black;">存活</span>期为 11.1 个月，标准化疗组为 7.5 个月。<span style="color: black;"><strong style="color: blue;">与标准化疗相比，Tedopi® 组中位<span style="color: black;">存活</span>期多出3.6个月，死亡<span style="color: black;">危害</span>降低41%</strong></span>，治疗<span style="color: black;">关联</span>的3~5级不良反应<span style="color: black;">显著</span>减少（<span style="color: black;"><strong style="color: blue;">38%</strong></span>&nbsp;vs&nbsp;68%)。</span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">超50%<span style="color: black;">病人</span>肿瘤病灶大幅缩小！新型癌症疫苗联合K药强强联手！</p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLH5AtuNqedOtMDKLPiabqty0OHz6sicw9v2GlVLDBt5mYdMABWsZaANRLZ7lnuia5HlQtacbXumkN5Q/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">IO102-IO103<span style="color: black;">是由于</span>前沿肿瘤疫苗<span style="color: black;">机构</span>IO Biotech<span style="color: black;">机构</span><span style="color: black;">开发</span>的新型免疫调节疫苗。其与PD-1<span style="color: black;">控制</span>剂帕博利珠单抗联用，在PD-L1高表达的肺腺癌<span style="color: black;">病人</span>中，<span style="color: black;">表示</span>出令人鼓舞的<span style="color: black;">初期</span>临床活性。其中PD-L1表达评分≥50%的<span style="color: black;">病人</span>效果更好。</span></p><span style="color: black;">此次<span style="color: black;">科研</span>结果在2023 年 IASLC 世界肺癌大会上<span style="color: black;">颁布</span>，15例未接受过治疗的晚期和转移性肺腺癌<span style="color: black;">病人</span>（<span style="color: black;">病人</span>的PD-L1表达评分≥50%）被确定可<span style="color: black;">评定</span>疗效，初步数据<span style="color: black;">表示</span>：</span><span style="color: black;">IO102-IO103疫苗与帕博利珠单抗联合治疗的<span style="color: black;"><strong style="color: blue;">客观缓解率为53.3%，这<span style="color: black;">显示</span>有超过半数的<span style="color: black;">病人</span>肿瘤大幅缩小或消失，有8例<span style="color: black;">病人</span><span style="color: black;">得到</span>部分缓解</strong></span><strong style="color: blue;">，26.7%的<span style="color: black;">病人</span>病情<span style="color: black;">得到</span>稳定。</strong></span><strong style="color: blue;"><span style="color: black;">两名治疗有效的<span style="color: black;">病人</span>，在初次给药后第21天，<span style="color: black;"><span style="color: black;">身体</span>的肿瘤标志物ctDNA水平便减少了94%</span>，</span></strong><span style="color: black;">疗效<span style="color: black;">明显</span>。<span style="color: black;">另外</span>，该联合疗法安全性<span style="color: black;">亦</span>较为良好。</span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">肿瘤病灶完全消失，mRNA疫苗让胰腺癌<span style="color: black;">病人</span><span style="color: black;">没</span>癌<span style="color: black;">存活</span>3年！</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLiaMDqrBZMqbf5peCsw1lIbYPKzTJ2SsZrR5hVknk5ric4sYpIvTaqY043pdfX8rMJOcia1ICUmQr8w/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;">近期</span>，<span style="color: black;">发布</span>在《自然》的一项最新<span style="color: black;">科研</span><span style="color: black;">发掘</span>，一种新的mRNA个体化新抗原疫苗，在治疗胰腺癌的I期临床<span style="color: black;">科研</span>中，表现出良好的安全性和出色的疗效。</span><span style="color: black;"><strong style="color: blue;">50%接受肿瘤切除后的胰腺癌<span style="color: black;">病人</span>在接种定制疫苗的18个月后<span style="color: black;">无</span>复发迹象。</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfLBa4noEEoIQNRMD5jOXXR56ASoSibZkXKwBtqu8IXibZvJ9FAHpO6bzfC2U9N8SnyCdhYIjs04GYdQ/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">图源《nature》杂志</span></strong></span></p><span style="color: black;">外界专家<span style="color: black;">叫作</span>，在经过30年的失败经历后，这是胰腺癌mRNA疫苗<span style="color: black;">第1</span>个可证明的成功<span style="color: black;">实验</span>，尽管仍<span style="color: black;">处在</span>初步<span style="color: black;">周期</span>，但这一<span style="color: black;">发掘</span><span style="color: black;">拥有</span>里程碑<span style="color: black;">道理</span>。</span><span style="color: black;">BNT122是个体化新抗原mRNA疫苗，当细胞<span style="color: black;">出现</span>癌变时会产生新抗原，而正常细胞中不会产生，这就致使人体的免疫系统<span style="color: black;">能够</span>识别这些新抗原并且对它们产生免疫反应。然而<span style="color: black;">非常多</span>肿瘤细胞中这种新抗原的表达水平很低，不足以激发人体免疫系统产生<span style="color: black;">剧烈</span>的免疫反应。</span><span style="color: black;"><span style="color: black;"><span style="color: black;">这里</span>项临床<span style="color: black;">实验</span>中，</span><strong style="color: blue;">19例胰腺癌<span style="color: black;">病人</span>采取手术切除后接受阿替利珠单抗，继而8剂疫苗，再接受改良FOLFIRINOX化疗12个周期，最后再接受1剂疫苗加强。</strong></span><span style="color: black;"><span style="color: black;">初步结果<span style="color: black;">表示</span>，</span><span style="color: black;"><strong style="color: blue;">16例<span style="color: black;">病人</span>（84%）在手术后9.4周接种了BNT122，50%（8/16）的<span style="color: black;">病人</span>检测<span style="color: black;">表示</span>诱导出新抗原特异性T细胞。</strong></span><span style="color: black;">在</span><span style="color: black;"><strong style="color: blue;">中位随访时间为18个月时，<span style="color: black;">得到</span>新抗原特异性免疫反应<span style="color: black;">病人</span>的<span style="color: black;">没</span>复发<span style="color: black;">存活</span>期（RFS）<span style="color: black;">明显</span>长于<span style="color: black;">没</span>疫苗激发免疫反应的<span style="color: black;">病人</span>。</strong></span><span style="color: black;"><span style="color: black;">得到</span>免疫反应组中位RFS尚未达到，未<span style="color: black;">得到</span>免疫反应组中位RFS为13.4个月。</span><span style="color: black;"><strong style="color: blue;">这<span style="color: black;">显示</span>有50%的<span style="color: black;">病人</span>18个月后<span style="color: black;">没</span>复发！</strong></span></span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">6人半年后<span style="color: black;">没</span>癌<span style="color: black;">存活</span>！ELI-002疫苗剑指高<span style="color: black;">危害</span>胰腺癌、结直肠癌</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLiaMDqrBZMqbf5peCsw1lIbYPKzTJ2SsZrR5hVknk5ric4sYpIvTaqY043pdfX8rMJOcia1ICUmQr8w/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">在2023年的癌症免疫治疗学会年会（SITC）上，一款美国新型癌症疫苗ELI-002用于治疗经局部治疗后仍残留癌细胞的高复发<span style="color: black;">危害</span>胰腺癌和结肠癌<span style="color: black;">病人</span>，在1期临床<span style="color: black;">实验</span>中表现良好，不仅激发了<span style="color: black;">病人</span>的免疫反应，还达到了良好的预防复发的效果。</span><span style="color: black;">其中，<span style="color: black;"><strong style="color: blue;">20例胰腺癌<span style="color: black;">病人</span>和5例结直肠癌<span style="color: black;">病人</span>进行6个月的疫苗治疗后，</strong></span></span><span style="color: black;"><strong style="color: blue;">77%的<span style="color: black;">病人</span>肿瘤标志物减少，其中6例<span style="color: black;">病人</span>达到了<span style="color: black;">没</span>癌状态。</strong></span><span style="color: black;"><span style="color: black;">长时间</span>随访<span style="color: black;">表示</span>，在接受了疫苗<span style="color: black;">加强</span>针后的<span style="color: black;">病人</span>中，75%的人保持了记忆T细胞。值得一提的是，<span style="color: black;"><strong style="color: blue;">这款疫苗<span style="color: black;">针对</span>针对KRAS突变<span style="color: black;">拥有</span>强大的<span style="color: black;">研发</span><span style="color: black;">潜能</span>。</strong></span></span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">国内首款！个性化肿瘤新抗原疫苗LK101注射液<span style="color: black;">获准</span>临床！</p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfLUTgZ95j30T5EYGIg8BiavQfYL8Lljc0z3ex5fH03JJ5ic4zZB3IVoARpDEToR9x52W77AKWHDakJw/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">2023年3月15日，据国家<span style="color: black;">药物</span>监督管理局<span style="color: black;">药物</span>审评中心（CDE）官网<span style="color: black;">表示</span>，北京立康生命自主<span style="color: black;">开发</span>的</span><span style="color: black;"><strong style="color: blue;">个性化肿瘤新抗原疫苗——“LK101注射液”</strong></span><span style="color: black;">的新药临床<span style="color: black;">实验</span>申请（IND）<span style="color: black;">获准</span>（受理号：CXSL2200612），</span><span style="color: black;"><strong style="color: blue;">用于治疗晚期实体瘤。</strong></span><span style="color: black;">据<span style="color: black;">没</span>癌家园获悉，</span><span style="color: black;"><strong style="color: blue;">这款<span style="color: black;">制品</span>是国内首个<span style="color: black;">获准</span>进入临床<span style="color: black;">周期</span>的个性化肿瘤新生抗原疫苗，<span style="color: black;">亦</span>是首个<span style="color: black;">获准</span>进入临床<span style="color: black;">周期</span>的完全个性化的mRNA编辑<span style="color: black;">制品</span></strong></span><span style="color: black;"><strong style="color: blue;">，是国内mRNA肿瘤疫苗<span style="color: black;">行业</span>的里程碑事件。</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/jn7Grkxp8cict5lSebhIVVYUyY0NhG5ia1SkVr0yNWu14ZgZ3wr3QojrRY7UqxNeICSYO42eCC1LgouHibdnHQT9Q/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></span></p><strong style="color: blue;"><span style="color: black;">图源来自国家<span style="color: black;">药物</span>监督管理局CDE官网</span></strong><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfLUTgZ95j30T5EYGIg8BiavQDK6v3kEzbF0x8Ay5ahtZJaYOCG1jWpB4LhsSFqJJbjkmyRic6EOImSQ/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">2022年12月22日，LK101注射液提交新药临床<span style="color: black;">科研</span>申请（IND）并获受理。这款个性化肿瘤新生抗原疫苗采用的是mRNA-DC（mRNA-树突状细胞）疫苗的形式，通过编码肿瘤新生抗原的mRNA体外转染树突细胞疫苗，兼具了mRNA疫苗和DC疫苗的<span style="color: black;">优良</span>。</span><span style="color: black;"><strong style="color: blue;">这款疫苗不仅安全性高、耐受性好，还能使<span style="color: black;">病人</span><span style="color: black;">得到</span><span style="color: black;">长时间</span>的抗癌效应。</strong></span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">肿瘤病灶完全消失或大幅缩小！癌症新抗原疫苗辅助治疗锦上添花！</p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfIGkTjCyeHkpIAPRJyFibX1UXy2hmhlspWQXXvKjEJgEjAkQb5jh7SBDSt4ds4xviamfclhzm2gG83g/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">2023年8月22日，美国知名生物<span style="color: black;">机构</span>宣布了一款</span><span style="color: black;"><strong style="color: blue;">个性化治疗性癌症疫苗（代号GNOS-PV02）</strong></span><span style="color: black;">与</span><span style="color: black;"><strong style="color: blue;">免疫<span style="color: black;">检测</span>点<span style="color: black;">控制</span>剂Keytruda（pembrolizumab）</strong></span><span style="color: black;">联用，在</span><span style="color: black;"><strong style="color: blue;">二线治疗晚期肝细胞癌（HCC）</strong></span><span style="color: black;">的1b/2a期临床<span style="color: black;">实验</span>中<span style="color: black;">得到</span>积极结果。</span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/LghKSGmMJfIGkTjCyeHkpIAPRJyFibX1Unia0SsAoYvSBGhOw4aSR5OseBqE9JXZibKz1nxSl5bicnthgZKDAicTXpw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">截图源自官网</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;"><strong style="color: blue;">GNOS-PV02是<strong style="color: blue;">一款DNA质粒递送的新抗原疫苗</strong><span style="color: black;">。</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">经过</span>对每例<span style="color: black;">病人</span>肿瘤进行测序，<span style="color: black;">发掘</span>基于<span style="color: black;">每一个</span><span style="color: black;">病人</span>独特的肿瘤突变产生的新抗原，<span style="color: black;">而后</span>将表达这些新抗原的DNA序列导入到DNA质粒中。</span></strong></span></span></p><span style="color: black;">此前，该<span style="color: black;">机构</span>的报告<span style="color: black;">叫作</span>，<span style="color: black;"><strong style="color: blue;">3例<span style="color: black;">病人</span>已实现完全缓解 (CR)，1例<span style="color: black;">病人</span>已<span style="color: black;">没</span>癌症，</strong></span>其肝脏和肺部病变缩小，对手术和放疗完全<span style="color: black;">敏锐</span>（二次可切除性）。</span><span style="color: black;">而此次更新的最新结果<span style="color: black;">表示</span>，<span style="color: black;"><strong style="color: blue;">另有4名<span style="color: black;">病人</span><span style="color: black;">得到</span>完全分子缓解。</strong></span>这<span style="color: black;">寓意</span>着<span style="color: black;">运用</span>非常<span style="color: black;">敏锐</span>的第三代循环肿瘤DNA（ctDNA）测试<span style="color: black;">没</span>法检测到这些<span style="color: black;">病人</span>的ctDNA。<span style="color: black;">按照</span>RECIST1.1<span style="color: black;">评定</span>，这4例<span style="color: black;">病人</span>中3例<span style="color: black;">得到</span>持久的部分缓解，1例为持久的<span style="color: black;">疾患</span>稳定。</span><span style="color: black;">此次代号为GT-30的临床<span style="color: black;">实验</span>中，共纳入34例病情<span style="color: black;">发展</span>的不可切除或转移性肝细胞癌<span style="color: black;">病人</span>，迄今为止，治疗结果<span style="color: black;">表示</span>，<span style="color: black;"><strong style="color: blue;">在32例可<span style="color: black;">评定</span>的<span style="color: black;">病人</span>中，完全缓解3例、部分缓解7例、<span style="color: black;">疾患</span>稳定9例</strong></span>和<span style="color: black;">疾患</span><span style="color: black;">发展</span>13例。</span><span style="color: black;"><span style="color: black;">按照</span> RECIST1.1 或 ctDNA 反应，32 例可<span style="color: black;">评定</span>的中有11例已实现完全反应、部分反应或完全分子反应。</span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率为71.4%！个性化癌症疫苗对泛癌种晚期实体瘤疗效<span style="color: black;">明显</span></p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfJLicEjBqWLsTlAvjm2wh3qRkutwCWB1JlM24Iiafj1ZDrAbuXbLw2icFpsBlqFibpyKdJ3jpBViaZ1j9g/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">浙江邵逸夫医院<span style="color: black;">科研</span>团队设计了一种基于肽的新生抗原疫苗iNeo-Vac-P01，并进行了一项前瞻性临床<span style="color: black;">实验</span>，共纳入22例标准治疗失败的泛癌种晚期实体瘤<span style="color: black;">病人</span>。利用iNeo人工智能疫苗设计平台、个体化多肽<span style="color: black;">药品</span>制备及质控体系为每例<span style="color: black;">病人</span>定制了iNeo-Vac-P01疫苗。</span><span style="color: black;">经治疗后，结果<span style="color: black;">表示</span>，<span style="color: black;"><strong style="color: blue;">22例晚期恶性肿瘤<span style="color: black;">病人</span>中，</strong></span>20例<span style="color: black;">没</span>不良反应<span style="color: black;">出现</span>或有轻微不良反应。<span style="color: black;"><strong style="color: blue;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率为71.4%，</strong></span><span style="color: black;"><strong style="color: blue;">中位<span style="color: black;">没</span><span style="color: black;">发展</span><span style="color: black;">存活</span>期为4.6个月而中位<span style="color: black;">存活</span>期中位数未达到。</strong></span></span><span style="color: black;"><span style="color: black;">科研</span><span style="color: black;">显示</span>，<span style="color: black;"><strong style="color: blue;"><span style="color: black;">针对</span>晚期实体瘤<span style="color: black;">病人</span><span style="color: black;">来讲</span>，iNeo-Vac-P01单药治疗是可行且安全的。</strong></span>它<span style="color: black;">能够</span>诱导T细胞介导的针对肿瘤新生抗原的免疫应答，可能<span style="color: black;">拥有</span>良好的抗肿瘤疗效。</span><span style="color: black;"><strong style="color: blue;">
            <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">博主</span>有话说</p>
      </strong></span><img src="https://mmbiz.qpic.cn/mmbiz_gif/LghKSGmMJfJYHKGl7w7ANCFJYgI4faUNu17PRS3Gy9dyj4JOdtxAiboX03icn0CmbX4JzL7oZSmvV05dsLwxDytQ/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><span style="color: black;">日前</span>，肿瘤疫苗临床<span style="color: black;">实验</span>正在如火如荼地开展，在不同肿瘤类型中取得疗效突破的好<span style="color: black;">信息</span><span style="color: black;">亦</span><span style="color: black;">持续</span>传来。新型肿瘤疫苗<span style="color: black;">已然</span>在延长晚期实体瘤<span style="color: black;">病人</span><span style="color: black;">存活</span>期方面展现了不错的实力。</span><span style="color: black;">随着肿瘤和免疫相互<span style="color: black;">功效</span>机制的深入理解，肿瘤疫苗将开启<span style="color: black;">精细</span>治疗的新时代。尽管新型肿瘤疫苗的<span style="color: black;">开发</span>和应用还存在<span style="color: black;">许多</span>的挑战，但随着对新抗原预测<span style="color: black;">科研</span>的<span style="color: black;">连续</span>深入和验证数据库<span style="color: black;">持续</span><span style="color: black;">累积</span>，以及树突细胞疫苗、mRNA疫苗、DNA疫苗等不同路径的尝试<span style="color: black;">已然</span>在临床上得到积极验证，新型肿瘤一毛的<span style="color: black;">开发</span>脚步正在<span style="color: black;">持续</span>加快，预计<span style="color: black;">将来</span>几年将迎来飞速发展，给广大肿瘤<span style="color: black;">病人</span>带来福音。</span><strong style="color: blue;"><span style="color: black;"><span style="color: black;">关联</span><span style="color: black;">文案</span>：<a style="color: black;"><span style="color: black;">解决</span>癌症有戏！病灶消失或延长<span style="color: black;">存活</span>期！8款新型疫苗有望<span style="color: black;">作为</span>肿瘤<span style="color: black;">病人</span>新<span style="color: black;">期盼</span>！</a></span></strong><a style="color: black;"><span style="color: black;"><strong style="color: blue;">癌症有可能被肿瘤疫苗<span style="color: black;">解决</span>吗？YES！多款树突细胞疫苗迎来井喷时代！</strong></span></a>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;"><strong style="color: blue;">重大突破！癌症有可能被新型疫苗终结？<span style="color: black;">没</span>癌时代离<span style="color: black;">咱们</span>越来越近！</strong></span></a></p><strong style="color: blue;">拓展阅读</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">除了<span style="color: black;">以上</span><span style="color: black;">说到</span>的</span><span style="color: black;"><strong style="color: blue;">个性化新抗原疫苗</strong></span></span><span style="color: black;">外，还有：</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">1. CAR-T疗法：</span></strong></span><span style="color: black;">CAR-T疗法（嵌合抗原受体T细胞免疫疗法）是一种治疗肿瘤的新型<span style="color: black;">精细</span>靶向治疗，只<span style="color: black;">不外</span>机制比PD-1更<span style="color: black;">繁杂</span>。<span style="color: black;">经过</span>基因工程技术将T细胞激活，并装上定位导航<span style="color: black;">安装</span>CAR（肿瘤嵌合抗原受体），将T细胞这个普通“战士”改<span style="color: black;">导致</span>“超级战士”，即CAR-T细胞，专门识别<span style="color: black;">身体</span>肿瘤细胞，并<span style="color: black;">有效</span>杀灭肿瘤细胞，从而达到治疗恶性肿瘤的目的。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">2. 肿瘤浸润淋巴细胞疗法：</span></strong></span><span style="color: black;">TILs疗法，相当于直接从战场上拉回有战斗经验的老兵，经过一轮“政治审查”和业务能力“大比拼”，把内奸、叛徒<span style="color: black;">尽可能</span>剔除出去，留下战斗力最强的，<span style="color: black;">供给</span>补给，再重新送回战场继续战斗；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">3. TCR-T疗法：</span></strong></span><span style="color: black;">相较于CAR-T疗法，TCR-T疗法在实体瘤治疗<span style="color: black;">行业</span>具备独特<span style="color: black;">优良</span>；</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">4. CTL疗法：</span></strong></span><span style="color: black;">利用癌细胞特有的、正常细胞上<span style="color: black;">无</span><span style="color: black;">或</span>含量很低的蛋白质做诱饵，把外周血中那“万里挑一”的真正能抗癌的淋巴细胞，挑选出来，<span style="color: black;">而后</span>在体外进一步改良和扩增，<span style="color: black;">而后</span>回输给<span style="color: black;">病人</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">若想<span style="color: black;">认识</span><span style="color: black;">更加多</span>关于细胞免疫疗法的<span style="color: black;">关联</span>临床<span style="color: black;">实验</span>及临床技术请<span style="color: black;">连续</span>关注</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">没</span>癌家园（400-626-9916）</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">。</span></strong></span></p><span style="color: black;"><strong style="color: blue;">本文为<span style="color: black;">没</span>癌家园原创，转载需授权！</strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">参考文献</span></strong></span></p><span style="color: black;">1.https://www.onclive.com/view/novel-immunomodulatory-vaccine-plus-pembrolizumab-shows-early-activity-in-pd-l1-high-nsclc-adenocarcinoma</span><span style="color: black;">2.https://www.targetedonc.com/view/new-phase-1-findings-show-promise-of-cancer-vaccines-in-kras-mutations</span><span style="color: black;">3.https://www.geneostx.com/geneos-therapeutics-announces-eight-of-34-patients-to-achieve-complete-response-complete-molecular-response-or-secondary-resectability-in-ongoing-clinical-trial-of-personalized-therapeutic-cancer-v/</span><span style="color: black;">4.https://www.onclive.com/view/personalized-neoantigen-vaccine-induces-continued-responses-in-pretreated-advanced-hcc</span><span style="color: black;">5.https://www.nature.com/articles/s41467-023-39196-9</span><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;"><span style="color: black;">没</span>癌家园提醒癌友们</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">国内细胞免疫治疗技术，<span style="color: black;">包含</span><span style="color: black;">CAR-T细胞（除上市的三款CAR-T外）、树突细胞疫苗、NK细胞、TILs细胞、TCR-T细胞治疗、癌症疫苗等技术</span>均<span style="color: black;">处在</span>临床试验<span style="color: black;">周期</span>，未获准在医院正式<span style="color: black;">运用</span>。国内<span style="color: black;">病人</span><span style="color: black;">能够</span>参加正规临床<span style="color: black;">实验</span>，在<span style="color: black;">大夫</span>的监管下<span style="color: black;">运用</span>，<span style="color: black;">没</span>癌家园网不<span style="color: black;">举荐</span><span style="color: black;">病人</span>冒然尝试任何医疗<span style="color: black;">公司</span>和<span style="color: black;">开发</span><span style="color: black;">公司</span>的收费治疗。</strong></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><strong style="color: blue;">热门<span style="color: black;">举荐</span></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"></p><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">扫码关注<span style="color: black;">没</span>癌家园</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">我帮你抗癌，你关注我到<span style="color: black;">恢复</span>~</p>分享、<span style="color: black;">保藏</span>、点赞、在看安排一下？<img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;"><img src="data:image/svg+xml,%3C%3Fxml version=1.0 encoding=UTF-8%3F%3E%3Csvg width=1px height=1px viewBox=0 0 1 1 version=1.1 xmlns=http://www.w3.org/2000/svg xmlns:xlink=http://www.w3.org/1999/xlink%3E%3Ctitle%3E%3C/title%3E%3Cg stroke=none stroke-width=1 fill=none fill-rule=evenodd fill-opacity=0%3E%3Cg transform=translate(-249.000000, -126.000000) fill=%23FFFFFF%3E%3Crect x=249 y=126 width=1 height=1%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E" style="width: 50%; margin-bottom: 20px;">

wrjc1hod 发表于 2024-9-30 09:45:21

感谢楼主的分享！我学到了很多。

b1gc8v 发表于 2024-10-3 16:37:37

我赞同你的看法，你的智慧让人佩服，谢谢分享。

nykek5i 发表于 2024-10-8 23:58:16

哈哈、笑死我了、太搞笑了吧等。

查看完整版本: 2023年值得期待的10款癌症疫苗，病灶消失或延长存活期，瞄准多样癌种！